Abstract
A new form (ACR-CH) of anticancer drug administration for treatment of breast cancer is prepared, the new dosage form of ACR-CH comprised 12.5 mg/ml of activated carbon, 5 mg/ml of polyvinylpyrrolidone and 5 mg/ml of aclarubicin (ACR) in saline. ACR-CH distributes less amount of ACR in blood and systemic organs than ACR aqueous solutionin (ACR-SOL) does. ACR-CH and ACR-SOL were studied on the acute toxicity. Some doses of ACR-CH and ACR-SOL were injected subcutaneously into the back of mice. Survival rate and general conditions were observed during 14 days after the injection. The mice were subjected to autopsy. The LD50 values of ACR-CH and ACR-SOL calculated following Litchfield-Wilcoxon method were 83.5 mg/kg and 43.5 mg/kg, respectively. Except for the recovery of body weight, there was no difference between the two dosage form in the intoxication symptomes and the autopsy findings. It was concluded that ACR-CH was adimistrated more safely than ACR-SOL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
